Amibegron API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Amibegron API 121524-08-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Amibegron. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Amibegron
- Synonyms:
- Cas Number:
- 121524-08-1
- DrugBank number:
- DB05395
- Unique Ingredient Identifier:
- PDQ3ME68U3
General Description:
Amibegron, identified by CAS number 121524-08-1, is a notable compound with significant therapeutic applications. Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in depression, irritable bowel syndrome (IBS), and obesity. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Amibegron functions by: SR 58611 has positive chronotropic effect which is mainly of peripheral origin and can be attributed to a baroreceptor-mediated reflex due to the beta3-adrenoceptor mediated vasodilation with an increase in sympathetic tone and a reduction in vagal tone to the heart. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Amibegron belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative, classified under the direct parent group Phenoxyacetic acid derivatives. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Phenoxyacetic acid derivatives subclass.
Categories:
Amibegron is categorized under the following therapeutic classes: Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Antidepressive Agents, Central Nervous System Depressants, Naphthalenes, Neurotransmitter Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Amibegron is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
